Trial reportMolecular psychiatry2024
Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.
Trial report in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02977299 (Augmentation Versus Switch), which is not on this map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The psychoneuroimmuneendocrine system, epigenetics, and the integration of morphogenetic fields: a systematic review of their role in unconscious ontogenesis.Frontiers in systems neuroscience · 2026Pooled it
- Rethinking Treatment-Resistant Depression: A Systematic Review of Novel Therapeutic Strategies and Precision Medicine Approaches.Actas espanolas de psiquiatria · 2025Pooled it
- Efficacy and safety of Toludesvenlafaxine extended-release tablets in the treatment of treatment-resistant depression.BMC psychiatry · 2025Trial
- Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial.BMC medicine · 2025Trial
- Latent class modeling of repetitive transcranial magnetic stimulation response trajectories in treatment-resistant depression.Journal of affective disorders · 2026Article
- Lactate metabolism and protein lactylation in programmed cell death: From novel mechanism to therapeutic strategies in human diseases.Clinical and translational medicine · 2026Review
- Accelerated TMS is associated with changes of subgenual cingulate-default mode network coupling in depression: an observational 7 Tesla fMRI study.European archives of psychiatry and clinical neuroscience · 2026Article
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.Molecular psychiatry · 2026Review
- Revisiting the Management of Treatment-Resistant Depression.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Article
- Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry.The lancet. Psychiatry · 2026Review
- When to Consider Transcranial Magnetic Stimulation for Youth With Depression Given Promising Data on Effectiveness-Authors' Reply.JAACAP open · 2026Article
- When to Consider Transcranial Magnetic Stimulation for Youth With Depression Given Promising Data on Effectiveness.JAACAP open · 2026Article
- Accelerated Theta Burst Stimulation Transcranial Magnetic Stimulation (iTBS-TMS)Brain, behavior, & immunity - health · 2026Article
- Next-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel.The Journal of clinical psychiatry · 2026Article
- Advances in the Clinical Application of Neurostimulation in Major Depression.Advances in experimental medicine and biology · 2026Review
- Efficacy of intranasal esketamine versus rTMS for treatment-resistant depression: analysis of individual participant data from two clinical trials.EClinicalMedicine · 2025Article
- The effects of rTMS on self-reported quality of life in younger and older adults with major depressive disorder.Psychological medicine · 2025Article
- Open letter to the Medical Services Advisory Committee regarding TMS Item Number regulations.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists · 2025Article
- Genetics of Response to ECT, TMS, Ketamine and Esketamine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2025Review
- Intermittent theta burst stimulation in adolescents and young adults with depressive disorders: protocol of a randomized, sham-controlled study with a sequential Bayesian design for adaptive trials.European archives of psychiatry and clinical neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Further research is needed to help improve both the standard of care and the outcome for patients with treatment-resistant depression. A particularly critical evidence gap exists with respect to whether pharmacological or non-pharmacological augmentation is superior to antidepressant switch, or vice-versa. The objective of this study was to compare the effectiveness of augmentation with aripiprazole or repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine XR (or duloxetine for those not eligible to receive venlafaxine) for treatment-resistant depression. In this multi-site, 8-week, randomized, open-label study, 278 subjects (196 females and 82 males, mean age 45.6 years (SD 15.3)) with treatment-resistant depression were assigned in a 1:1:1 fashion to treatment with either of these three interventions; 235 subjects completed the study. 260 randomized subjects with at least one post-baseline Montgomery-Asberg Depression Rating (MADRS) assessment were included in the analysis. Repetitive transcranial magnetic stimulation (score change (standard error (se)) = -17.39 (1.3) (p = 0.015) but not aripiprazole augmentation (score change (se) = -14.9 (1.1) (p = 0.069) was superior to switch (score change (se) = -13.22 (1.1)) on the MADRS. Aripiprazole (mean change (se) = -37.79 (2.9) (p = 0.003) but not repetitive transcranial magnetic stimulation augmentation (mean change (se) = -42.96 (3.6) (p = 0.031) was superior to switch (mean change (se) = -34.45 (3.0)) on the symptoms of depression questionnaire. Repetitive transcranial magnetic stimulation augmentation was shown to be more effective than switching antidepressants in treatment-resistant depression on the study primary measure. In light of these findings, clinicians should consider repetitive transcranial magnetic stimulation augmentation early-on for treatment-resistant depression.Trial registration: ClinicalTrials.gov, NCT02977299.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.